To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Dexamethasone-Enhanced Adductor Canal Block for Persistent Pain After ACL Reconstruction

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
June 2025

Dexamethasone-Enhanced Adductor Canal Block for Persistent Pain After ACL Reconstruction

Vol: 307| Issue: 6| Number:101| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Dexamethasone as an additive to bupivacaine in an ultrasound-guided adductor canal block for the management of persistent pain after arthroscopic reconstruction of the anterior cruciate ligament: a randomized, double-blind study.

BMC Anesthesiol . 2025 Apr 24;25(1):208.

Contributing Authors:
S Elsawy A Abdelwahab Y Hamdi RAA Hamed

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Ninety patients undergoing arthroscopic ACL reconstruction were randomized to receive either a 20 ml mixture of 0.25% bupivacaine plus 8 mg dexamethasone (n=45) or 20 ml of 0.25% bupivacaine with saline (n=45) via ultrasound-guided adductor canal block. The primary outcome was the dynamic visual analog score (DVAS) at 1 month. Secondary outcomes included postoperative VAS scores at 24 hours, DVAS ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue